supporting image

Alzheimer's Disease (AD)

Over 6 million people in the US are living with Alzheimer disease (AD)1, and over 80 million adults between 50-70 years whose biggest health fear, other than cancer, is AD2.

We want to help them all.

Labcorp is proud to offer the first available ATN Profile

Our ATN Profile is based on years of research on individual markers that, together, reflect the biological changes consistent with Alzheimer’s disease. 
 

484400

ATN Profile

This profile is used to assist in determining the presence or absence of key biological changes that are consistent with Alzheimer's disease pathology

View ATN Profile


Each of the biomarker tests are orderable individually.

  • 505725

    Beta Amyloid 42/40 Ratio, Plasma

    Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a plasma patient sample and computes the ratio of those proteins, providing an indication of amyloid pathology for Alzheimer’s disease

    View Test Details

    483745

    Phosphorylated Tau 181 (pTau-181), Plasma

    This test detects and quantifies pTau181 proteins in plasma, which has been demonstrated to be predictive in differentiating Alzheimer’s from other dementias

    View Test Details

    140555

    Neurofilament Light Chain, Plasma

    NfL, in the context of Alzheimer’s disease, provides an indication of disease severity by measuring the current level of neurodegeneration

    View Test Details

Early Onset Alzheimer's NGS Diagnostic Test (630557)

AD is a complex and heterogeneous disease, influenced by many genetic and environmental factors. Early onset familial AD (presenting between 25-60) occurs in less than 2% of AD cases. This test analyzes three genes (amyloid protein precursor (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2)) to detect pathogenic variants that cause autosomal dominant early onset Alzheimer's disease. Testing may be considered to confirm a diagnosis of early onset Alzheimer's disease in symptomatic individuals.

Learn More

APOE Alzheimer’s Risk (504040)

This test detects the presence of the Apolipoprotein E (APOE)-4 variant, which is associated with increased risk of late-onset (age >60-65) Alzheimer's disease (AD). Testing may be considered for patients with dementia to supplement information from clinical and other evaluations. APOE has multiple roles, including lipid transport in the blood and the brain. The APOE4 variant increases the risk for late-onset Alzheimer's disease and may contribute to the pathology of the disease through influence on β-amyloid, inflammation, or other processes.

Learn More

Beta Amyloid 42/40 Ratio, CSF (505560)

Labcorp’s Beta-Amyloid 42/40 Ratio test quantifies the amount of beta-amyloid 42 and 40 proteins in a CSF patient sample and computes the ratio of those proteins, providing an indication of disease progression. Studies have shown strong correlation of CSF beta-amyloid levels to PET scan results. This test can be a surrogate to more costly PET scan imaging.

Learn More

Providing clear, objective answers to clinicians, patients and families

Labcorp is working hard, combining the power of new high precision technology with artificial intelligence to advance diagnostic testing in order to provide clear, objective answers to clinicians, patients, and families.

We are working with blood-based biomarkers, like pTau and NfL, and collaborating with pharmaceutical and diagnostic partners to develop tests that identify, diagnose and monitor patients with AD.

References

  1. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/facts-figures
  2. Anderson LA, Day KL, Beard RL, et.al. “The Public's Perceptions About Cognitive Health and Alzheimer's Disease Among the U.S. Population: A National Review”. The Gerontologist. 2009; 49(S1): S3–S11.
  3. Janelidze S, et.al. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 202; 26(3):379-386.
  4. Thijssen EH, et.al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat Med. 2020; 26(3): 387–397.
  5. Karikair, TK, et.al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020 May;19(5):422-433.
  6. Cullen, N.C., et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging 1, 114–123 (2021).
  7. Palmqvist S, Zetterberg H, Mattsson N, et.al. “Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.” Neurology. 2015;85:1–10
  8. Hansson O, Seibyl J, Stomrud E, et.al. “CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.” Alzheimer’s & Dementia. 2018; 14(11): P1470-1481.

 Explore More Neurodegenerative Capabilities

ALS, Ataxias, & Huntington's

Genetics can play a significant role in the development of certain neurodegenerative diseases. In some cases, genetic testing may help confirm a diagnosis.

Learn More

Muscular Dystrophy

Characterized by progressive muscle loss and weakness, our tests can detect the genetic mutations that cause the most common forms.

Learn More

Multiple Sclerosis

While no single test can diagnose multiple sclerosis, lab tests may help doctors rule out other diseases and confirm a diagnosis.

Learn More

Biomarkers for Drug Development

The increasing prevalence of neurodegenerative diseases has fueled the need for advanced research into pharmaceutical solutions and related neuro biomarkers.

Learn More